杨淑娟,杨丽霞,石燕昆,王先梅,陈长征,郭瑞威

• 1:解放军第九二零医院心内科(原成都军区昆明总医院)

摘要(Abstract)：

目的回顾性分析高同型半胱氨酸血症和H型高血压对急性ST段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)预后的影响。方法回顾性分析2015年6月至2016年12月在成都军区昆明总医院心内科行直接PCI的急性ST段抬高型心肌梗死患者511例,其中226例资料完整,符合要求。按患者血清同型半胱氨酸(homocysteine,Hcy)水平是否≥15.0μmol/L及是否合并高血压分为H型高血压组68例,单纯高Hcy组54例,单纯高血压组64例及非高Hcy、非高血压组40例。比较四组患者基线资料,PCI术中及住院期间相关数据,术后1、3个月左心室射血分数,术后3个月内因再发心肌梗死、靶血管再次血运重建和再发心绞痛而再住院次数及死亡患者数。结果四组患者糖尿病、高脂血症、冠心病家族史、心绞痛史、平均首次医疗接触时间、平均入门至球囊扩张时间、心肌总缺血时间、肌酸激酶峰值、术前血糖水平、用药情况及血脂水平等比较,差异均无统计学意义(均P>0.05)。四组患者性别、平均年龄、高血压病史、吸烟比例、血清肌酸酐水平、Hcy水平、尿酸水平及术后3个月内再住院次数等比较,差异均有统计学意义(均P<0.05)。H型高血压组Hcy水平大于单纯高血压组[21.0(17.3,28.5)μmol/L比11.7(8.8,13.1)μmol/L,P<0.001],非高Hcy、非高血压组[21.0(17.3,28.5)μmol/L比10.7(8.3,11.9)μmol/L,P<0.001];单纯高Hcy组Hcy水平大于单纯高血压组[19.2(16.6,24.4)μmol/L比11.7(8.8,13.1)μmol/L,P<0.001],非高Hcy、非高血压组[19.2(16.6,24.4)μmol/L比10.7(8.3,11.9)μmol/L,P<0.001],差异均有统计学意义。H型高血压组患者3个月内再住院次数大于单纯高Hcy组[(0.80±0.51)次比(0.53±0.50)次,P=0.006],单纯高血压组[(0.80±0.51)次比(0.59±0.50)次,P=0.030]及非高Hcy、非高血压组[(0.80±0.51)次比(0.53±0.51)次,P=0.010],差异均有统计学意义。多重回归分析显示,冠心病家族史(偏回归系数0.428,标准化偏回归系数0.188,t=2.696,P=0.008)、多支血管病变(偏回归系数0.465,标准化偏回归系数0.293,t=4.176,P<0.001)、术前血糖水平(偏回归系数0.032,标准化偏回归系数0.230,t=3.255,P=0.001)、Hcy水平(偏回归系数0.006,标准化偏回归系数0.153,t=2.195,P=0.030)及术前低密度脂蛋白胆固醇水平(偏回归系数0.035,标准化偏回归系数0.142,t=2.059,P=0.041)为术后3个月内再住院次数的影响因素。结论高同型半胱氨酸血症和高血压对急性ST段抬高型心肌梗死患者预后的影响有协同作用,当高同型半胱氨酸血症合并高血压(即H型高血压)时对急性ST段抬高型心肌梗死患者预后的影响更显著。

关键词(KeyWords)： 高同型半胱氨酸血症;H型高血压;ST段抬高型心肌梗死;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 云南省中青年学术和技术带头人后备人才基金(2014HB035)

作者(Author): 杨淑娟,杨丽霞,石燕昆,王先梅,陈长征,郭瑞威

参考文献(References)：

• [1]方芳,张伟,乔旭柏,等.急性冠状动脉综合征患者易损斑块的临床病理分析.中华心血管病杂志,2011,39(9):802-806.
• [2]王国位,刘宏斌.冠心病患者426例远期随访研究及影响因素分析.中国介入心脏病学杂志,2013,21(4):230-234.
• [3]HumphreyLL, FuR, Rogers K,et al. Homocysteine level and coronary heart disease incidence:a systematic review and metaanalysis. Mayo Clin Proc,2008,83(11):1203-1212.
• [4]SunY, Chien KL,HsuHC,et al. Use of serum homocysteine to predict stroke,coronary heart disease and death in ethnic Chinese 12-year prospective cohort study. Circ J,2009,73(8):1423-1430.
• [5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南.中华心血管病杂志, 2015,45(5):380-393.
• [6]刘力生,吴兆苏,朱鼎良,等.中国高血压防治指南2010.中华心血管病杂志,2011,39(7):579-616.
• [7]MoranA,ZhaoD,Gu D,et al. The future impact of population growth and aging on coronary heart disease in China:projections from the coronary heart disease policy model-China. BMC Public Health,2008,8:394.
• [8]Graham IM,Daly LE,Refsum HM,et al. Plasma homocysteine asa risk factor for vascular disease. The European concerted action project. JAMA,1997,277(22):1775-1781.
• [9]PedrinelliR, BalloP, FiorentiniC, etal.Hypertensionand acute myocardial infarction:an overview. J Cardiovasc Med(Hagerstown),2012,13(3):194-202.
• [10]WolfPA,D'AgostinoRB, BelangerAJ, etal.Probability of stroke:a risk profile from the Framingham Study. Stroke,1991,22(3):312-318.
• [11]YanoY,StamlerJ, GarsideDB, etal.Isolatedsystolic hypertension in young and middle-aged adults and 31-year risk for cardiovascular mortality:the Chicago Heart Association detection project in Industry study. J Am Coll Cardiol,2015,65(4):327-335.
• [12]AgenoW, BecattiniC, Brighton T,et al. Cardiovascular risk factors and venous thromboembolism:a meta-analysis. Circulation,2008,117(1):93-102.
• [13]Jacobs P,Wood L,Bick R. Homocysteine in vascular disease:an emerging clincal perspective. Cardiovasc J S Afr,2006,17(3):135-139.
• [14]SenU, MoshalKS, TyagiN, etal.Homocysteine-induced myofibroblast differentiation in mouse aortic endothelial cells. J Cell Physiol,2006,209(3):767-774.
• [15]丁国锋,毛艳华,石斗飞,等.老年高血压并缺血性脑卒中患者血浆同型半胱氨酸变化的临床意义.山东医药,2006,46(1):30-31.
• [16]Pizzolo F,Firso S,Olivieri O,et al. Homocysteine,traditional risk factors and impaired renal function in coronary artery disease. Eur J Clin Inves,2006,36(10):698-702.
• [17]DalyC,FitzqeraldAP, O'CallaghanP,etal.Homocysteine increases the risk associated with hyperlipidaemia. Eur J Cardiovasc Prev Rehabil,2009,16(2):150-155.
• [18]许海燕,陈在嘉.高同型半胱氨酸血症与冠心病研究进展.现代诊断与治疗,1999,10(3):156-157.